Organon rises after agreeing to sell postpartum bleeding device to Laborie for up to $465 mln

Shares of healthcare firm Organon OGN.N rise 2% to $6.85 premarket

Co says it will sell its JADA System, a device used to treat postpartum bleeding, to Laborie Medical Technologies for up to $465 million

Deal includes $440 mln upfront, $25 mln tied to 2026 sales targets – OGN

OGN says ~100 of it's employees will move to Laborie as part of the agreement

The JADA System, which OGN acquired in 2021, is used to manage postpartum hemorrhage, a serious complication after childbirth - OGN

The transaction is expected to close in the first quarter of 2026, pending regulatory approvals, co says

Up to last close, stock down ~55% YTD